* FDA sets Jan 31, 2011, as action date * Contrave to compete with Vivus, Arena experimental drugs
June 17 (Reuters) - Orexigen Therapeutics Inc (OREX.O) said the U.S. health regulator has assigned Jan. 31, 2011, as the review date for the new drug application of its experimental obesity drug.
Contrave is a pill that combines the antidepressant Wellbutrin, known generically as bupropion, with a sustained-release version of naltrexone, an opioid blocker used to treat alcoholism and other addictions.
Shares of Orexigen closed at $4.67 Wednesday on Nasdaq. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Aradhana Aravindan) ((firstname.lastname@example.org; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: email@example.com))